Abstract
15-oxo-Lipoxin A4 (15-oxo- LXA4) has been identified as a natural metabolite of the fatty acid signaling mediator Lipoxin A4. Herein, we report a total synthesis of the methyl ester of 15-oxo-LXA4 to be used in investigations of potential electrophilic bioactivity of this metabolite. The methyl ester of 15-oxo-LXA4 was synthesized in a convergent 15 step (9 steps longest linear) sequence starting from 1-octyn-3-ol and 2-deoxy-D-ribose with Sonogashira and Suzuki cross-couplings of a MIDA boronate as key steps.
Keywords: eicosanoid, electrophile, palladium-catalyzed coupling, MIDA boronate
Graphic Abstract

Arachidonic acid (AA) plays a key role in cell signaling, as it has been shown to be the biosynthetic source of eicosanoids that mediate the function of leukocytes and other inflammatory responses via G-protein-coupled receptor (GPCR) ligand activity. These AA metabolites include prostaglandins, prostacyclins, thromboxanes and leukotrienes.1 One class of AA-derived mediators termed lipoxins A4 and B4 ((5S,6R,15S)-trihydroxy-eicosa-7E,9E,11Z,13E-tetraenoic acid and (5S,14R,15S)-trihydroxy-6E,8Z,10E,12E-eicosatetraenoic acid, or LXA4 and LXB4) are trihydroxytetraenes produced by the successive lipoxygenase oxidations of AA2 (5-LOX and 12/15-LOX) by stimulated leukocytes. When administered as pure synthetic compounds, these species display pleiotropic actions described3 as anti-inflammatory and pro-resolving and, because of low concentrations and rapid degradation, are difficult to detect4, 5 in vivo. They, along with the 15(R)-stereoisomers6 (15-epi-LXA4), have been investigated as leads7 for the treatment8 of several chronic and acute inflammatory conditions.
In vivo lipoxin A4 is rapidly metabolized9 via 15-hydroxyprostaglandin dehydrogenase10 (15-PGDH) oxidation of the 15(S)-hydroxy to 15-keto (Fig. 1), followed by reduction of the neighboring C13–14 double bond and finally reduction of the 15-keto to a hydroxyl. While the initial oxidation itself results in ablation of GPCR ligand activity,11 the formation of an α ,β-unsaturated keto group in the 15-oxo intermediate suggests the potential for alternative electrophilic reactivity. Lipids containing α,β-unsaturated carbonyls have been shown to form covalent Michael adducts with thiol-containing enzymes12 in addition to glutathione (via glutathione S-transferase13). Electrophilic signaling mediators typically exert effects at higher concentrations than GPCR-specific activity, but the effects can be pleiotropic and have extended kinetics. Recent work14–16 has shown structurally similar oxo-eicosatetraeneoates (e.g. 15-oxoETEs) to modulate inflammatory responses via electrophilic signaling, and given our long-standing interest in electrophilic redox signaling17, 18 the de novo synthesis of a representative member of this structural family to explore this potential was encouraged.
Figure 1.

Structures of lipoxin A4 (LXA4) and 15-oxo-lipoxin A4 (15-oxo-LXA4) produced in vitro by enzymatic oxidation with 15-PGDH/NAD+. 15-oxo-LXA4 is expected to contain electrophilic site(s) in conjugation to the keto group.
Multiple synthetic approaches to the parent LXA419–22 and isomers23, 24 (as well as di- and tri-hydroxy docosapentaenoates25, 26 and docosahexaenoates27) have been described in the literature, providing useful starting points. As we intended to utilize palladium-catalyzed coupling reactions to provide the desired (E,E,Z,E)-tetraene stereochemistry, an additional development of interest was the use of N -methylimidodiacetyl (MIDA)-protected boronates28, 29 as part of an iterative, modular approach to polyene natural products, which we considered as a novel approach to the tetraene core. Finally, concerns about lipophilicity and cell permeability in administering the product to biological targets prioritized the methyl ester over the free acid. With these considerations in mind a synthetic approach to 15-oxo-(5S,6R)-dihydroxy-eicosa-7E,9E,11Z,13E-tetraenoate methyl ester (15-oxo-LXA4Me, 1 ) was designed.
In our retrosynthetic design (Fig. 2) the target was broken into two portions: an eight-carbon haloalkene ester (2) and a twelve-carbon MIDA-protected boronic ester (3) which could serve as a Suzuki coupling partner. Haloalkene ester 2 was developed from a structurally similar aldehyde30 that we proposed to transform directly to an iodovinyl group through a Takai reaction.31, 32 The (5S,6R) diol unit could be obtained in turn from chiral pool 2-deoxy-D-ribose (4) and protected to ensure specific oxidation and retention of stereochemistry.
Figure 2.

Retrosynthetic analysis of 15-oxo-LXA4Me (1).
Both of the interstitial conjugated E,Z double bonds of the tetraene were potentially accessible through halovinyl MIDA boronates, but limited commercial availability of the required cis-halovinyl MIDA boronate discouraged a direct double-MIDA approach. After considering similar work,23 we proposed dien-yne 3 which could be derived from inexpensive and commercially available racemic 1-octyn-3-ol (5). While several literature precedents also took the precaution of protecting the alcohol of 5 (e.g. as a TBDMS ether) a palladium-catalyzed coupling approach did not seem to require such protection;33 and instead the alcohol would essentially act as a protecting group for the desired carbonyl. The final steps of alkyne reduction, specific oxidation, and deprotection could then proceed after assembling and coupling the framework.
The synthesis of iodovinyl 2 (Scheme 1) commenced with protection of the diol of 2-deoxy-D-ribose (4) as an acetonide34 by etherification with isopropenyl methyl ether in the presence of catalytic PPTS (pyridinium p -toluenesulfonate, 44%). The hemiacetal portion of the protected ribose 6 was then homologated34 via Wittig-type conditions with methyl (triphenylphosphoranylidene) acetate and catalytic benzoic acid (86%). The resulting α ,β-unsaturated ester 7 was reduced30 quantitatively with hydrogen in the presence of rhodium on alumina catalyst and subsequently oxidized to aldehyde 8 by either Swern30 (oxalyl chloride, DMSO) or Parikh-Doering35, 36 (sulfur trioxide-pyridine complex, DMSO) conditions in similar yields (76%). Finally under Takai conditions31, 37 aldehyde 8 was transformed to iodovinyl ester 2 in reasonable yield (63%, Z :E 1:5). The Z :E product ratio was continued through the next step although it could be separated chromatographically. Note that the analogous bromovinyl Takai conditions were not investigated.
Scheme 1: Reagents and conditions:

(a) isopropenyl methyl ether, cat. PPTS, EtOAc, rt, 44%; (b) Ph3P=CHCO2Me, cat. BzOH, MeCN, reflux, 86%; (c) cat. Rhodium (5w/w% Al2O3), 1 atm H2, MeOAc, rt, quant.; (d) (COCl)2, TEA, DMSO/ CH2Cl2, −78°C to rt or SO3-Pyr, TEA, DMSO/CH2Cl2, 0°C to rt, 76%; (e) CHI3, CrCl2, rt, 1,4-dioxane-THF, 63% (E:Z ratio 5:1)
Racemic 1-octyn-3-ol (5) was brominated38 (Scheme 2) using N -bromosuccinimide in acetone with catalytic silver nitrate. Several precedents suggested that lithium aluminum anhydride in combination with aluminum chloride would reduce the bromo-alkyne; however, this combination was unreactive in our hands. Instead the less-common method39 of DIBAL with aluminum chloride gave virtually quantitative yields (80% over two steps). The resulting bromo-vinyl allylic alcohol 10 was then coupled29 by standard Sonogashira methods to trimethysilylacetylene. Afterwards, the TMS group was deprotected40 with potassium carbonate (88% over two steps) before repeating the Sonogashira protocol with bromo (or iodo-)vinyl MIDA boronate 12 to afford the desired dien-yne 3 in reasonable yield (67%).
Scheme 2: Reagents and conditions:

(a) NBS, 10% AgNO3, acetone, 0°C to rt, 3h; (b) DIBAL (4 eq.), AlCl3 (2 eq.), ether, 0°C to rt, 80% for 2 steps; (c) TMSA, 5% Pd(PPh3)4, 10% CuI, piperidine, THF, rt; (d) K2CO3, MeOH, rt, 88% for 2 steps; (e) 12 , 5% Pd(PPh3)4, 10% CuI, piperidine, THF, rt, 67%. MIDA = (O2CCH2)2NMe
The coupling of substrates 2 and 3 (Scheme 3) proceeded after first hydrolyzing the MIDA protecting group of 3 with sodium hydroxide to afford the boronic acid, which was coupled to iodovinyl 2 by Suzuki methods29 in 64% yield. The resultant trien-yne 13 retained the Z :E isomer ratio of 2 (e.g. 1:5; 3 was apparently stereospecific) but could be isomerized22 to an all-trans configuration (clean by 1H) through exposure to catalytic iodine in benzene. Trien-yne 13 was subsequently reduced to tetraene 14 via a solvolytic zinc-based reduction (75%). The zinc used to produce the Zn(Cu/Ag) alloy was activated23, 41 immediately prior to reaction by cleaning of the zinc surface with acid followed by reaction with cupric acetate and silver nitrate. While stereoselective, this method was not consistently scalable in our hands, and attempts at larger scale were met with noticeably variable yields. Note that intermediate 14, as an acetonide-protected methyl ester of 15-rac-Lipoxin A4, provides a convenient route to the corresponding diastereomeric LXA4.
Scheme 3: Reagents and conditions:

(a) (i) 3, 1 M NaOH; (ii) 2, 5% Pd(OAc)2, 10% XPhos, NaOH, THF, rt,; (b) cat. I2, PhH, rt, 64% for 2 steps (Z:E 1:5 to clean E ); (c) Zn(Cu/Ag) alloy, MeOH-water, rt, 75%; (d) Dess-Martin Periodinane, CH2Cl2, rt, 82%; (e) 2M aq. HCl, MeOH, rt, 63%
Oxidation of the unprotected alcohol proceeded cleanly using Dess-Martin periodinane (82%) and the acetonide protecting group was removed (HCl in methanol, 63%) to yield 1 with only minimal formation of a cyclized δ -lactone side product (removed by chromatography). The spectral data of the keto- tetraene compounds 1 and 15 confirmed our expectations: the UV-Vis spectra was red-shifted from 312 nm to 345 nm, and the 1H NMR spectrum of the vinyl region showed protons shifted downfield (δ6.69 to δ7.64 ppm), indicating significant deshielding characteristic of electron withdrawal. However, a general instability of the tetraenone frequently led to impurities in the post-oxidation steps, and products from 14 on were thus treated with minimal heating and stored as methanol solutions, cold, in reduced-light conditions and under argon or nitrogen to minimize intermolecular reaction. Indeed, a prior synthesis of 5-oxoETE noted42, 43 the facile cis -trans isomerization of the keto-diene, and a recent report44 on a keto-triene described the inherent instability of an analogous Z-isomer in an electron deficient polyene as being an electronic rather than steric effect. This relative configurational stability may be further investigated as additional electrophilic polyenes are synthesized.
In conclusion we have developed a successful synthesis of 15-oxo-lipoxin A4 methyl ester in preparation to evaluate the potential electrophilic reactivity and biological signaling associated with this and related α,β-unsaturated ketones. Our methods obtained a 3.7% overall final yield from a convergent 15 step (9 steps longest linear) sequence, and our use of a MIDA boronate strategy simplified our palladium-catalyzed coupling approach to the tetraene motif.
Supplementary Material
Highlights.
First total synthesis of keto-tetraene 15-oxo-Lipoxin A4 has been achieved.
Synthetic approach: iterative palladium-catalyzed coupling using a MIDA boronate
Dess-Martin oxidation of 15-position hydroxyl to electrophilic keto
Key steps: Sonogashira, Suzuki couplings; Zinc(Copper/Silver) reduction of trien-yne
Acknowledgements:
We thank Chris J. Dayer and Ben J. Tydings for general assistance, Sonia R. Salvatore for assistance with HPLC-HRMS, and Andrew Robak (Keuka College) for helpful discussions. In addition we thank Laurel Ann Povazan Scholnick of the University of Pittsburgh Library System for assistance in finding several key references. This work was supported by the National Institutes of Health (R01-HL132550 (BAF), R21AI122071 (SGW), R01-GM125944, R01-DK112854 (FJS) and AHA 17GRN33660955 (FJS)). SRW, SGW, FJS and BAF acknowledge financial interest in Complexa Inc.
Footnotes
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
References
- 1.Hanna VS; Hafez EA A. J Adv Res 2018, 11, 23. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Samuelsson B; Dahlen S; Lindgren J; Rouzer C; Serhan CN Science 1987, 237, 1171. [DOI] [PubMed] [Google Scholar]
- 3.Ryan A; Godson C Curr Opin Pharmacol 2010, 10, 166. [DOI] [PubMed] [Google Scholar]
- 4.Homann J; Suo J; Schmidt M; de Bruin N; Scholich K; Geisslinger G; Ferreirós N PLoS One 2015, 10, e0143141. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Sasaki A; Fukuda H; Shiida N; Tanaka N; Furugen A; Ogura J; Shuto S; Mano N; Yamaguchi H Anal Bioanal Chem 2015, 407, 1625. [DOI] [PubMed] [Google Scholar]
- 6.Serhan CN Prostaglandins Leukot Essent Fatty Acids 2005, 73, 141. [DOI] [PubMed] [Google Scholar]
- 7.Serhan CN Nature 2014, 510, 92. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Barnig C; Levy BD Expert Rev Clin Immunol 2013, 9, 491. [DOI] [PubMed] [Google Scholar]
- 9.Serhan CN; Fiore S; Brezinski DA; Lynch S Biochemistry 1993, 32, 6313. [DOI] [PubMed] [Google Scholar]
- 10.Clish CB; Levy BD; Chiang N; Tai H-H; Serhan CN J Biol Chem 2000, 275, 25372. [DOI] [PubMed] [Google Scholar]
- 11.Maddox JF; Serhan CN J Exp Med 1996, 183, 137. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Higdon A; Diers, Anne R.; Oh, Joo Y.; Landar, A.; Darley-Usmar, Victor M. Biochem J 2012, 442, 453. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Hwa Lee S; Rangiah K; Williams MV; Wehr AY; DuBois RN; Blair IA Chem Res Toxicol 2007, 20, 1665. [DOI] [PubMed] [Google Scholar]
- 14.Snyder NW; Golin-Bisello F; Gao Y; Blair IA; Freeman BA; Wendell SG Chem Biol Interact 2015, 234, 144. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Wendell SG; Golin-Bisello F; Wenzel S; Sobol RW; Holguin F; Freeman BA J Biol Chem 2015, 290, 5868. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Wei C; Zhu P; Shah SJ; Blair IA Mol Pharmacol 2009, 76, 516. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Schopfer FJ; Cipollina C; Freeman BA Chem Rev 2011, 111, 5997. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Groeger AL; Cipollina C; Cole MP; Woodcock SR; Bonacci G; Rudolph TK; Rudolph V; Freeman BA; Schopfer FJ Nature Chem Bio 2010, 6, 433. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Adams J; Fitzsimmons BJ; Girard Y; Leblanc Y; Evans JF; Rokach J J Am Chem Soc 1985, 107, 464. [Google Scholar]
- 20.Corey EJ; Su W-G Tetrahedron Lett 1985, 26, 281. [Google Scholar]
- 21.Nicolaou KC; Webber SE J Chem Soc, Chem Comm 1985, 297.
- 22.Nicolaou KC; Veale CA; Webber SE; Katerinopoulos H J Am Chem Soc 1985, 107, 7515. [Google Scholar]
- 23.Rodríguez, A. R.; Spur, B. W. Tetrahedron Lett 2001, 42, 6057. [Google Scholar]
- 24.Duffy CD; Guiry PJ MedChemComm 2010, 1, 249. [Google Scholar]
- 25.Ogawa N; Sugiyama T; Morita M; Suganuma Y; Kobayashi Y J Org Chem 2017, 82, 2032. [DOI] [PubMed] [Google Scholar]
- 26.Aursnes M; Tungen JE; Vik A; Colas R; Cheng CY; Dalli J; Serhan CN; Hansen TV J Nat Prod 2014, 77, 910. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Rodriguez AR; Spur BW Tetrahedron Lett 2018, 59, 1143. [Google Scholar]
- 28.Gillis EP; Burke MD J Am Chem Soc 2007, 129, 6716. [DOI] [PubMed] [Google Scholar]
- 29.Lee SJ; Gray KC; Paek JS; Burke MD J Am Chem Soc 2008, 130, 466. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Mori K; Takeuchi T Tetrahedron 1988, 44, 333. [Google Scholar]
- 31.Takai K; Nitta K; Utimoto K J Am Chem Soc 1986, 108, 7408. [DOI] [PubMed] [Google Scholar]
- 32.Nicolaou KC; Ramphal JY; Palazon JM; Spanevello RA Angew Chem Int Edit 1989, 28, 587. [Google Scholar]
- 33.Alami M; Crousse B; Linstrumelle G; Mambu L; Larchevêque M Tetrahedron: Asymmetry 1997, 8, 2949. [Google Scholar]
- 34.Corey EJ; Marfat A; Goto G; Brion F J Am Chem Soc 1980, 102, 7984. [Google Scholar]
- 35.Parikh JR; Doering W v. E. J Am Chem Soc 1967, 89, 5505. [Google Scholar]
- 36.Fuwa H; Sasaki M; Tachibana K Tetrahedron 2001, 57, 3019. [Google Scholar]
- 37.Gillis EP; Burke MD J Am Chem Soc 2008, 130, 14084. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Guilford WJ; Bauman JG; Skuballa W; Bauer S; Wei GP; Davey D; Schaefer C; Mallari C; Terkelsen J; Tseng J-L; Shen J; Subramanyam B; Schottelius AJ; Parkinson JF J Med Chem 2004, 47, 2157. [DOI] [PubMed] [Google Scholar]
- 39.Yan W; Li Z; Kishi Y J Am Chem Soc 2015, 137, 6219. [DOI] [PubMed] [Google Scholar]
- 40.Gong J-X; Wang H-Y; Yao L-G; Li X-W; Guo Y-W Synlett 2016, 27, 391. [Google Scholar]
- 41.Boland W; Schroer N; Sieler C; Feigel M Helv Chim Acta 1987, 70, 1025. [Google Scholar]
- 42.Khanapure SP; Powell WS; Rokach J J Org Chem 1998, 63, 8976. [DOI] [PubMed] [Google Scholar]
- 43.Khanapure SP; Shi X-X; Powell WS; Rokach J J Org Chem 1998, 63, 337. [Google Scholar]
- 44.Feceu A; Sangster LE; Martin DB C. Org Lett 2018, 20, 3151. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
